<div id="readability-page-1"><p>TFG Asset Management GP Ltd bought a new position in shares of  Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 138,375 shares of the company's stock, valued at approximately $1,317,000. Dyne Therapeutics makes up   0.2% of TFG Asset Management GP Ltd's holdings, making the stock its 28th biggest position. TFG Asset Management GP Ltd owned about 0.10% of Dyne Therapeutics as of its most recent filing with the Securities &amp; Exchange Commission.</p><p>Other institutional investors and hedge funds have also recently modified their holdings of the company. RA Capital Management L.P. boosted its position in shares of  Dyne Therapeutics by 52.2% during the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company's stock valued at $101,613,000 after acquiring an additional 3,333,248 shares during the last quarter.  Braidwell LP lifted its position in  Dyne Therapeutics by 431.6% during the first quarter. Braidwell LP now owns 3,621,344 shares of the company's stock valued at $37,879,000 after purchasing an additional 2,940,162 shares during the last quarter.  Armistice Capital LLC lifted its position in  Dyne Therapeutics by 187.0% during the first quarter. Armistice Capital LLC now owns 2,768,000 shares of the company's stock valued at $28,953,000 after purchasing an additional 1,803,482 shares during the last quarter.  Vestal Point Capital LP purchased a new position in  Dyne Therapeutics in the 1st quarter worth approximately $18,828,000.  Finally, Saturn V Capital Management LP bought a new position in shares of  Dyne Therapeutics in the 2nd quarter worth $13,856,000. Hedge funds and other institutional investors own  96.68% of the company's stock. </p><div><p><span></span><span>Get <strong>Dyne Therapeutics</strong> alerts:</span></p></div><h2>Dyne Therapeutics Stock Down 1.4%</h2><p>DYN opened at $19.42 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $27.59. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The business's 50-day moving average price is $19.05 and its 200-day moving average price is $14.22. The company has a market cap of $2.77 billion, a P/E ratio of -5.31 and a beta of 1.30. </p><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.05.  On average, equities analysts expect that  Dyne Therapeutics, Inc. will post -3.44 EPS for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of analysts have recently issued reports on the stock. Robert W. Baird  set a $30.00 price objective on shares of Dyne Therapeutics in a report on Monday. Lifesci Capital upgraded Dyne Therapeutics to a &#34;strong-buy&#34; rating in a research report on Tuesday, October 14th. Royal Bank Of Canada upped their price objective on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 6th. Oppenheimer upgraded Dyne Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and increased their price objective for the company from $11.00 to $40.00 in a research report on Wednesday. Finally, HC Wainwright boosted their target price on Dyne Therapeutics from $46.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned  a Buy rating, two have assigned  a Hold rating and one  has assigned  a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $38.59.</p><p><b>Get Our Latest Analysis on DYN</b></p><h2>About Dyne Therapeutics</h2> (Free Report)<p>Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Dyne Therapeutics</li><li>Quiet Period Expirations Explained</li><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li><li>What Do S&amp;P 500 Stocks Tell Investors About the Market? </li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>3 Warren Buffett Stocks to Buy Now</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>TFG Asset Management GP Ltd acquired 138,375 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in Q2, valued at $1,317,000. Dyne Therapeutics constitutes 0.2% of TFG's holdings. Other institutional investors like RA Capital, Braidwell LP, and Armistice Capital also increased their stakes. Dyne Therapeutics' stock is rated as a 'Moderate Buy' with an average target price of $38.59. The company focuses on therapeutics for genetically driven muscle diseases.</p>

TFG Asset Management GP Ltd Acquires New Stake in Dyne Therapeutics, Inc. $DYN